RA Hayward, TP Hofer, S Vijan - Annals of internal medicine, 2006 - Am Coll Physicians Recent national recommendations have proposed that physicians should titrate lipid therapy
to achieve low-density lipoprotein (LDL) cholesterol levels less than 1.81 mmol/L (<70
mg/dL) for patients at very high cardiovascular risk and less than 2.59 mmol/L (<100 ... Cited by 99 - Related articles - BL Direct - All 6 versions
I Abraha, I Bonacini, A Montedori - The Lancet, 2006 - Elsevier The lack of efficacy of statins in women treated for primary prevention should not, however, come
as a surprise. Several prospective observational studies, including the Framingham Heart
Study, 3 have shown that the incidence of new major coronary events in women is lower ... Cited by 11 - Related articles - All 9 versions
CR Sirtori, L Calabresi - The Lancet, 2006 - Elsevier A formal answer from Japan comes from the MEGA trial in today's Lancet. 6 Haruo Nakamura
and colleagues did a randomised open-label study, investigating pravastatin (10–20 mg per
day) added to a low-lipid diet in primary prevention in individuals with moderate ... Cited by 16 - Related articles - All 11 versions
[CITATION] Safety and efficacy of atorvastatin induced very low LDL-C levels. A post hoc …
CM Ballantyne - The American journal of cardiology, 1998 - Elsevier Clinical trials provide evidence on methods for risk assessment of coronary artery disease and
on interventions used to decrease risk. Plaque rupture, which leads to either progression of coronary
artery disease or myocardial infarction, is the critical biologic event in the pathophysiology ... Cited by 36 - Related articles - BL Direct - All 5 versions
- ►onlinejacc.org BM Scirica, DA Morrow, CP Cannon, KK Ray, MS … - Journal of the American …, 2006 - Elsevier The Pravastatin or Atorvastatin Evaluation and Infection Trial–Thrombolysis In Myocardial Infarction
22 (PROVE IT–TIMI 22) study randomized 4,162 patients, stabilized after ACS, to either intensive
statin therapy (atorvastatin 80 mg) or moderate statin therapy (pravastatin 40 mg). ... Cited by 55 - Related articles - BL Direct - All 8 versions
- ►lipidgeneticsclinic.ca [PDF] P Deedwania, P Barter, R Carmena, JC Fruchart, SM … - The Lancet, 2006 - Elsevier The TNT study was a prospective, double blind, parallel-group trial done at 256 sites in 14 countries
between April, 1998, and August, 2004, with a median follow-up of 4·9 years. 10 001 patients
were enrolled aged 35–75 years with clinically evident coronary heart disease. Our ... Cited by 108 - Related articles - All 11 versions
H Nakamura, K Arakawa, H Itakura, A Kitabatake, Y … - The Lancet, 2006 - Elsevier 3966 patients were randomly assigned to the diet group and 3866 to the diet plus pravastatin
group. Mean follow-up was 5·3 years. At the end of study, 471 and 522 patients had
withdrawn, died, or been lost to follow-up in the diet and diet plus pravastatin groups, ... Cited by 107 - Related articles - All 26 versions
- ►onlinejacc.org SD Wiviott, CP Cannon, DA Morrow, KK Ray, MA … - Journal of the American …, 2005 - Elsevier The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial
Infarction 22 (PROVE IT-TIMI 22) study compared intensive therapy (atorvastatin, 80 mg) and
moderate therapy (pravastatin, 40 mg) in patients after ACS. Patients treated with ... Cited by 89 - Related articles - BL Direct - All 10 versions
LF McMahon Jr, RA Hayward, S Saint, ME Chernew, … - Am J Manag Care, 2005 - ajmc.com “Healthcare costs continue to rise and are approach- ing a crisis.” This oft-repeated refrain appears
in both popular and professional media and commentaries. However, the cost-containment discussion
thus far has failed to acknowledge in any substantive way the role physicians play in ... Cited by 13 - Related articles - View as HTML - All 4 versions
